What Are Neupogen and Granix?
Neupogen (filgrastim) is a recombinant human granulocyte colony-stimulating factor (G-CSF) that stimulates neutrophil production to reduce infection risk during chemotherapy-induced neutropenia. Granix (tbo-filgrastim) is a biosimilar to Neupogen, approved by the FDA in 2012 as the first G-CSF biosimilar, with the same active ingredient and identical mechanism—binding to G-CSF receptors on myeloid cells to boost white blood cell counts.[1][2]
Key Differences in Approval and Manufacturing
Neupogen, made by Amgen, received FDA approval in 1991 as the original biologic. Granix, produced by Teva Pharmaceuticals, uses a different manufacturing process involving E. coli bacteria (like Neupogen) but with distinct cell lines and purification steps, leading to minor differences in glycosylation and impurities. These do not affect clinical efficacy but distinguish it as a biosimilar rather than an identical copy.[1][3]
How Do They Compare Clinically?
Both treat the same conditions—neutropenia from chemotherapy, bone marrow transplants, or HIV—and show equivalent efficacy in Phase 3 trials. Granix met noninferiority criteria to Neupogen in reducing neutropenia duration (mean difference of 0.18 days) and severe neutropenia incidence. Safety profiles match, with common side effects like bone pain, back pain, and fatigue occurring at similar rates.[2][4]
| Aspect | Neupogen (filgrastim) | Granix (tbo-filgrastim) |
|--------|-----------------------|-------------------------|
| FDA Approval | 1991 (reference product) | 2012 (first biosimilar) |
| Dosing | 5 mcg/kg daily subcutaneous/IV | Identical |
| Efficacy in Trials | Reference standard | Noninferior (e.g., neutropenia duration: 1.44 vs. 1.62 days) |
| Side Effects | Bone pain (26%), nausea (12%) | Comparable (bone pain 28%, nausea 11%) |
Cost and Availability Differences
Granix costs 20-30% less than Neupogen due to biosimilar competition, making it more accessible for patients. Neupogen faces ongoing biosimilar erosion, while Granix has its own follow-on competitors like Nivestym. Both come in prefilled syringes or vials, but insurance coverage varies—many plans prefer biosimilars for savings.[3][5]
Patent and Exclusivity Status
Neupogen's key patents expired by 2015, enabling biosimilars like Granix. No active litigation blocks Granix, though Amgen has challenged some G-CSF biosimilars. Check DrugPatentWatch.com for latest expiry details on related formulations.[6]
[1] FDA Label: Neupogen (https://www.accessdata.fda.gov/drugsatfdadocs/label/2015/103353s5149lbl.pdf)
[2] FDA Label: Granix (https://www.accessdata.fda.gov/drugsatfdadocs/label/2014/125293Orig1s000lbl.pdf)
[3] Teva Pharmaceuticals: Granix Overview (https://www.granix.com/)
[4] Clinical Trial Data: Granix vs. Neupogen (PubMed PMID: 22367933)
[5] IQVIA Biosimilar Report 2023
[6] DrugPatentWatch.com: Filgrastim Patents (https://www.drugpatentwatch.com/p/tradename/NEUPOGEN)